Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study von Gettinger, Scott, Horn, Leora, Jackman, David, Spigel, David, Antonia, Scott, Hellmann, Matthew, Powderly, John, Heist, Rebecca, Sequist, Lecia V, Smith, David C, Leming, Philip, Geese, William J, Yoon, Dennis, Li, Ang, Brahmer, Julie

Volltext

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab von TOPALIAN, Suzanne L, SZNOL, Mario, LEMING, Philip D, LIPSON, Evan J, PUZANOV, Igor, SMITH, David C, TAUBE, Janis M, WIGGINTON, Jon M, KOLLIA, Georgia D, GUPTA, Ashok, PARDOLL, Drew M, SOSMAN, Jeffrey A, McDERMOTT, David F, STEPHEN HODI, F, KLUGER, Harriet M, CARVAJAL, Richard D, SHARFMAN, William H, BRAHMER, Julie R, LAWRENCE, Donald P, ATKINS, Michael B, POWDERLY, John D

Volltext

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma von FLAHERTY, Keith T, LEE, Sandra J, FENGMIN ZHAO, SCHUCHTER, Lynn M, FLAHERTY, Lawrence, KEFFORD, Richard, ATKINS, Michael B, LEMING, Philip, KIRKWOOD, John M

Volltext

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab von Topalian, Suzanne L, Sznol, Mario, McDermott, David F, Kluger, Harriet M, Carvajal, Richard D, Sharfman, William H, Brahmer, Julie R, Lawrence, Donald P, Atkins, Michael B, Powderly, John D, Leming, Philip D, Lipson, Evan J, Puzanov, Igor, Smith, David C, Taube, Janis M, Wigginton, Jon M, Kollia, Georgia D, Gupta, Ashok, Pardoll, Drew M, Sosman, Jeffrey A, Hodi, F Stephen

Volltext

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602) von SLINGLUFF, Craig L, LEE, Sandra, FENGMIN ZHAO, CHIANESE-BULLOCK, Kimberly A, OLSON, Walter C, BUTTERFIELD, Lisa H, WHITESIDE, Theresa L, LEMING, Philip D, KIRKWOOD, John M

Volltext

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer von Topalian, Suzanne L, Hodi, F. Stephen, Brahmer, Julie R, Gettinger, Scott N, Smith, David C, McDermott, David F, Powderly, John D, Carvajal, Richard D, Sosman, Jeffrey A, Atkins, Michael B, Leming, Philip D, Spigel, David R, Antonia, Scott J, Horn, Leora, Drake, Charles G, Pardoll, Drew M, Chen, Lieping, Sharfman, William H, Anders, Robert A, Taube, Janis M, McMiller, Tracee L, Xu, Haiying, Korman, Alan J, Jure-Kunkel, Maria, Agrawal, Shruti, McDonald, Daniel, Kollia, Georgia D, Gupta, Ashok, Wigginton, Jon M, Sznol, Mario

Volltext

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term s... von Brahmer, Julie, Horn, Leora, Jackman, David, Spigel, David, Antonia, Scott, Hellmann, Matthew, Powderly, John, Heist, Rebecca, Sequist, Lecia, Smith, David C., Leming, Philip, Geese, William J., Yoon, Dennis, Li, Ang, Gettinger, Scott

Volltext

The utility of circulating tumor DNA analysis to identify BRAF mutations in malignant melanoma von Kirby, Eric, Leming, Philip D.

Volltext

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial von Hodi, F. Stephen, Lee, Sandra, McDermott, David F, Rao, Uma N, Butterfield, Lisa H, Tarhini, Ahmad A, Leming, Philip, Puzanov, Igor, Shin, Donghoon, Kirkwood, John M

Volltext

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer von Gettinger, Scott N, Horn, Leora, Gandhi, Leena, Spigel, David R, Antonia, Scott J, Rizvi, Naiyer A, Powderly, John D, Heist, Rebecca S, Carvajal, Richard D, Jackman, David M, Sequist, Lecia V, Smith, David C, Leming, Philip, Carbone, David P, Pinder-Schenck, Mary C, Topalian, Suzanne L, Hodi, F Stephen, Sosman, Jeffrey A, Sznol, Mario, McDermott, David F, Pardoll, Drew M, Sankar, Vindira, Ahlers, Christoph M, Salvati, Mark, Wigginton, Jon M, Hellmann, Matthew D, Kollia, Georgia D, Gupta, Ashok K, Brahmer, Julie R

Volltext

An independent oncology second opinion program: 2020 pilot project von Leming, Philip D., Hunt, Jillian M., Herzog, Thomas J., Jazieh, Abdul-Rahman, Barrett, William

Volltext

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit von Grossman, Douglas, Okwundu, Nwanneka, Bartlett, Edmund K, Marchetti, Michael A, Othus, Megan, Coit, Daniel G, Hartman, Rebecca I, Leachman, Sancy A, Berry, Elizabeth G, Korde, Larissa, Lee, Sandra J, Bar-Eli, Menashe, Berwick, Marianne, Bowles, Tawnya, Buchbinder, Elizabeth I, Burton, Elizabeth M, Chu, Emily Y, Curiel-Lewandrowski, Clara, Curtis, Julia A, Daud, Adil, Deacon, Dekker C, Ferris, Laura K, Gershenwald, Jeffrey E, Grossmann, Kenneth F, Hu-Lieskovan, Siwen, Hyngstrom, John, Jeter, Joanne M, Judson-Torres, Robert L, Kendra, Kari L, Kim, Caroline C, Kirkwood, John M, Lawson, David H, Leming, Philip D, Long, Georgina V, Marghoob, Ashfaq A, Mehnert, Janice M, Ming, Michael E, Nelson, Kelly C, Polsky, David, Scolyer, Richard A, Smith, Eric A, Sondak, Vernon K, Stark, Mitchell S, Stein, Jennifer A, Thompson, John A, Thompson, John F, Venna, Suraj S, Wei, Maria L, Swetter, Susan M

Volltext

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases von Faries, Mark B., Mozzillo, Nicola, Kashani-Sabet, Mohammed, Thompson, John F., Kelley, Mark C., DeConti, Ronald C., Lee, Jeffrey E., Huth, James F., Wagner, Jeffrey, Dalgleish, Angus, Pertschuk, Daniel, Nardo, Christopher, Stern, Stacey, Elashoff, Robert, Gammon, Guy, Morton, Donald L.

Volltext

Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing von Kashani-Sabet, Mohammed, Leachman, Sancy A, Stein, Jennifer A, Arbiser, Jack L, Berry, Elizabeth G, Celebi, Julide T, Curiel-Lewandrowski, Clara, Ferris, Laura K, Grant-Kels, Jane M, Grossman, Douglas, Kulkarni, Rajan P, Marchetti, Michael A, Nelson, Kelly C, Polsky, David, Seiverling, Elizabeth V, Swetter, Susan M, Tsao, Hensin, Verdieck-Devlaeminck, Alexandra, Wei, Maria L, Bar, Anna, Bartlett, Edmund K, Bolognia, Jean L, Bowles, Tawnya L, Cha, Kelly B, Chu, Emily Y, Hartman, Rebecca I, Hawryluk, Elena B, Jampel, Risa M, Karapetyan, Lilit, Kheterpal, Meenal, Lawson, David H, Leming, Philip D, Liebman, Tracey N, Ming, Michael E, Sahni, Debjani, Savory, Stephanie A, Shaikh, Saba S, Sober, Arthur J, Sondak, Vernon K, Spaccarelli, Natalie, Usatine, Richard P, Venna, Suraj, Kirkwood, John M

Volltext

Multivariate prognostic factors in metastatic uveal melanoma (UM) von Deeb, Ayham, Abdel Karim, Nagla, Leming, Philip D., Bhatt, Ananta, Namad, Tariq, Xie, Changchun, Hunt, Jillian, Correa, Zelia, Augsburger, James

Volltext

Sargramostim plus Ipilimumab vs Ipilimumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial von Hodi, F. Stephen, Lee, Sandra, McDermott, David F., Rao, Uma N., Butterfield, Lisa H., Tarhini, Ahmad A., Leming, Philip, Puzanov, Igor, Shin, Donghoon, Kirkwood, John M.

Volltext

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial von Hodi, F. Stephen, Kluger, Harriet, Sznol, Mario, Carvajal, Richard, Lawrence, Donald, Atkins, Michael, Powderly, John, Sharfman, William, Puzanov, Igor, Smith, David, Leming, Philip, Lipson, Evan, Taube, Janis, Anders, Robert, Horak, Christine, Jiang, Joel, McDermott, David, Sosman, Jeffrey, Brahmer, Julie, Pardoll, Drew, Topalian, Suzanne

Volltext

Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 von Hodi, F. Stephen, Lee, Sandra J., McDermott, David F., Rao, Uma N. M., Butterfield, Lisa H., Tarhini, Ahmad A., Leming, Philip D., Puzanov, Igor, Kirkwood, John M.

Volltext

Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608 von Hodi, F. Stephen, Lee, Sandra J., McDermott, David F., Rao, Uma N. M., Butterfield, Lisa H., Tarhini, Ahmad A., Leming, Philip D., Puzanov, Igor, Kirkwood, John M.

Volltext

A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma (E1602) von Slingluff, Craig L., Lee, Sandra, Zhao, Fengmin, Chianese-Bullock, Kimberly A., Olson, Walter, Butterfield, Lisa H., Whiteside, Theresa, Leming, Philip D., Kirkwood, John M.

Volltext